AU2019398451B2 - Amorphous solid dispersions - Google Patents

Amorphous solid dispersions Download PDF

Info

Publication number
AU2019398451B2
AU2019398451B2 AU2019398451A AU2019398451A AU2019398451B2 AU 2019398451 B2 AU2019398451 B2 AU 2019398451B2 AU 2019398451 A AU2019398451 A AU 2019398451A AU 2019398451 A AU2019398451 A AU 2019398451A AU 2019398451 B2 AU2019398451 B2 AU 2019398451B2
Authority
AU
Australia
Prior art keywords
dispersion
iti
excipient
depression
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019398451A
Other languages
English (en)
Other versions
AU2019398451A1 (en
Inventor
Peng Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of AU2019398451A1 publication Critical patent/AU2019398451A1/en
Application granted granted Critical
Publication of AU2019398451B2 publication Critical patent/AU2019398451B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019398451A 2018-12-14 2019-12-13 Amorphous solid dispersions Active AU2019398451B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779930P 2018-12-14 2018-12-14
US62/779,930 2018-12-14
PCT/US2019/066247 WO2020123952A1 (en) 2018-12-14 2019-12-13 Amorphous solid dispersions

Publications (2)

Publication Number Publication Date
AU2019398451A1 AU2019398451A1 (en) 2021-07-15
AU2019398451B2 true AU2019398451B2 (en) 2024-12-05

Family

ID=71077112

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019398451A Active AU2019398451B2 (en) 2018-12-14 2019-12-13 Amorphous solid dispersions

Country Status (9)

Country Link
EP (1) EP3893878A4 (https=)
JP (1) JP7523440B2 (https=)
KR (1) KR20210103501A (https=)
CN (1) CN113473988A (https=)
AU (1) AU2019398451B2 (https=)
CA (1) CA3123085A1 (https=)
IL (1) IL283927A (https=)
MX (1) MX2021006886A (https=)
WO (1) WO2020123952A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112584837A (zh) * 2018-08-31 2021-03-30 细胞内治疗公司 新方法
CN115671057A (zh) 2022-10-19 2023-02-03 四川迈可隆生物科技有限公司 一种卢美哌隆药物组合物、长效微球缓释制剂及其制备方法
CN118566395B (zh) * 2024-08-02 2024-10-25 则正(济南)生物科技有限公司 测定甲苯磺酸卢美哌隆口崩片中杂质含量的方法、应用和系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4001281A1 (en) * 2016-08-09 2022-05-25 Teva Pharmaceuticals International GmbH Solid state forms of lumateperone ditosylate salt and preparation thereof
US11331316B2 (en) * 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
JP2020513023A (ja) * 2017-04-10 2020-04-30 ドクター・レディーズ・ラボラトリーズ・リミテッド ルマテペロンp−トシラートの非晶質形態および固体分散体
US11655251B2 (en) * 2017-11-27 2023-05-23 Egis Gyogyszergyar Zrt. Method for the production of lumateperone and its salts
CN112584837A (zh) * 2018-08-31 2021-03-30 细胞内治疗公司 新方法

Also Published As

Publication number Publication date
EP3893878A1 (en) 2021-10-20
IL283927A (en) 2021-07-29
JP7523440B2 (ja) 2024-07-26
JP2022512239A (ja) 2022-02-02
MX2021006886A (es) 2021-09-14
CA3123085A1 (en) 2020-06-18
EP3893878A4 (en) 2022-08-17
KR20210103501A (ko) 2021-08-23
WO2020123952A1 (en) 2020-06-18
AU2019398451A1 (en) 2021-07-15
CN113473988A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
US12472178B2 (en) Amorphous solid dispersions
TWI719349B (zh) Cftr調節劑之結晶形式及組合物
AU2019398451B2 (en) Amorphous solid dispersions
WO2020242935A1 (en) Methods of treatment for cystic fibrosis
BR112020014487A2 (pt) composições farmacêuticas para tratamento de fi-brose cística
EP3243824A1 (en) Solid forms of ibrutinib free base
RU2646491C2 (ru) Твердые дисперсии нерастворимого лекарственного средства и способы их приготовления
KR20110055448A (ko) 모사프라이드를 유효성분으로 함유하는 서방성 제제
WO2016169534A1 (en) Solid forms of amorphous empagliflozin
HK40060531A (zh) 无定形固体分散体
HK40011133A (en) Amorphous solid dispersions
CA3031777A1 (en) Crystalline form of olaparib
US9211290B2 (en) Solid dispersions of amorphous paroxetine mesylate
HK40011133B (zh) 无定形固体分散体
KR100805675B1 (ko) 클로피도그렐 베실레이트를 포함하는 약학 조성물 및 그의제조방법
WO2016206660A1 (en) Solid forms of amorphous canagliflozin

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)